Business intelligence
from24/7 Wall St.
3 days agoGilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
Wall Street analysts identify Gilead as undervalued with strong IP protection through 2036, while Amgen appears fairly valued after a 35% rally, and Oric presents opportunity despite competitor-driven selloff.